Studies on the behaviour of semicarbazide-sensitive amine oxidase in Sprague-Dawley rats treated with the monoamine oxidase inhibitor tranylcypromine

  • D. H. Fitzgerald
  • K. F. Tipton
  • G. A. Lyles
Part of the Journal of Neural Transmission. Supplement book series (NEURAL SUPPL, volume 52)


The possibility that increased levels of the activity of the semicarbazide-sensitive amine oxidase (SSAO) might, to some extent, compensate for the loss of monoamine oxidase (MAO) activity in the atypical form of Norrie Disease, was examined using the rat as a model. Long-term treatment with the MAO inhibitor tranylcypromine (1 mg/kg/day) resulted in sustained inhibition of MAO-A and MAO-B activities in liver and brain. After one week, the SSAO activity in heart had increased by 79% above the control levels. This increase was maintained for 3 weeks. Since such alterations might result from enzyme induction, the turnover of the enzyme was studied in cultured cells from rat aortic smooth muscle. The time-course of recovery of enzyme activity following irreversible inhibition by MDL 72145 corresponded to a half-life of approximately 6 days for this process.


Monoamine Oxidase Amine Oxidase SSAO Activity Plasma Amine Oxidase Inhibitor Tranylcypromine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Campbell JH, Campbell GR (1993) Culture techniques and their applications to studies of vascular smooth muscle. Clin Sci 85: 501–513PubMedGoogle Scholar
  2. Clarke DE, Lyles GA, Callingham BA (1982) A comparison of cardiac and vascular clorgyline resistant amine oxidase and monoamine oxidase. Biochem Pharmacol 31: 27–35PubMedCrossRefGoogle Scholar
  3. Elliott J, Fowden AL, Callingham BA, Sharman DF, Silver M (1991) Physiological and pathological influences on sheep plasma amine oxidase: effects of pregnancy and experimental allotoxan-induced diabetes mellitus. Res Vet Sci 50: 334–339PubMedCrossRefGoogle Scholar
  4. Hayes BE, Ostrow PT, Clarke DE (1983) Benzylamine oxidase in normal and atherosclerotic aortae. Exp Mol Pathol 38: 243–254PubMedCrossRefGoogle Scholar
  5. Lizcano JM, Balsa D, Tipton KF, Unzeta M (1991) The oxidation of dopamine by the semicarbazide-sensitive amine oxidase (SSAO) from rat vas deferens. Biochem Pharmacol 41: 1107–1110PubMedCrossRefGoogle Scholar
  6. Lewinsohn R (1977) Human serum amine oxidase, enzyme activity in severely burnt patients and in patients with cancer. Clin Chim Acta 81: 247–256PubMedCrossRefGoogle Scholar
  7. Lewinsohn R (1984) Mammalian monoamine oxidising enzymes, with special reference to benzylamine oxidase in human tissues. Brazil J Med Biol Res 17: 223–256Google Scholar
  8. Lewinsohn R, Glover V, Sandler M (1980) Development of benzylamine oxidase and monoamine oxidase A and B in man. Biochem Pharmacol 29: 1221–1230PubMedCrossRefGoogle Scholar
  9. Lyles GA, Callingham BA (1982) In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidases in rat cardiovascular tissues. Biochem Pharmacol 31: 1417–1424PubMedCrossRefGoogle Scholar
  10. McEwen CM Jr (1972) The soluble monoamine oxidase of human plasma and sera. Adv Biochem Psychopharmacol 5: 51–165Google Scholar
  11. Murphy DL, Wright C, Buchsbaum M, Costa J, Nichols A, Wyatt R (1976) Platelet and plasma amine activities in 680 normals; sex and age differences and stability over time. Biochem Med 16: 254–265CrossRefGoogle Scholar
  12. Murphy DL, Sims KB, Karoum F, de la Chapelle A, Norio R, Sankila E-M, Breakfield XO (1990) Marked amine and metabolite changes in Norrie disease patients with an X-chromosomal deletion affecting monoamine oxidase. J Neurochem 54: 242–247PubMedCrossRefGoogle Scholar
  13. Norrie G (1926) Causes of blindness in children. Acta Opthalmol (Copenhagen) 5: 357–386CrossRefGoogle Scholar
  14. Suzuki O, Matsumoto T (1984) Some properties of benzylamine oxidase in human aorta. Biogenic Amines 1: 249–257Google Scholar
  15. Tipton KF (1985) Determination of monoamine oxidase. Meth Find Exp Clin Pharmacol 7: 361–367Google Scholar
  16. Warburg M (1966) Norries disease: a congenital, progressive, occuloacoustic, cerebral degeneration. Acta Opthalmol (Copenh) [Suppl] 89: 1–47Google Scholar
  17. Zis AP, Gold PW, Paul SM, Goodwin FK, Murphy DL (1980) Elevation of human plasma and platelet amine oxidase activity in response to intravenous dopamine. Life Sci 28: 371–376CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 1998

Authors and Affiliations

  • D. H. Fitzgerald
    • 1
    • 1
  • K. F. Tipton
    • 1
  • G. A. Lyles
    • 2
  1. 1.Department of BiochemistryTrinity CollegeDublin 2Ireland
  2. 2.Department of Pharmacology and Clinical Pharmacology, Ninewells Hospital and Medical SchoolUniversity of DundeeDundeeScotland, UK

Personalised recommendations